Latest Market Engagement News

Castile Resources has reported substantial increases in gold, copper, and bismuth resources at its Rover 1 Project, while advancing plans for refined bismuth production amid tightening global supply due to Chinese export controls.

Control Bionics reports a strong start to FY26 with nearly 10% revenue growth, expanded US reimbursement coverage, and advancing commercialization of its NeuroNode and NeuroStrip technologies.

IperionX has boosted titanium powder production capacity by 60% and secured US$75 million in Department of War funding to scale up to 1,400 tonnes per annum by 2027, aiming to become the largest and lowest-cost US titanium producer.

BluGlass Limited reports a robust project pipeline exceeding US$100 million, bolstered by initial orders from Collins Aerospace and Infleqtion Inc, alongside strategic board appointments and a $6 million R&D tax rebate.

Aurora Labs has advanced its micro gas turbine propulsion program with critical durability testing, a new Defence contract phase, and a strategic $5.5 million capital raise to scale manufacturing and commercialisation.

Li-S Energy has marked a milestone with the production of Australia’s first lithium metal foils and expanded its footprint in the global defense sector, supported by new manufacturing capabilities and strategic partnerships.

Forrestania Resources has rapidly expanded its gold portfolio across Western Australia, boosting its resource base from 24koz to over 593koz in just 14 weeks, backed by a strategic $8.61 million capital raise.

Gathid Ltd reports a stable customer base despite a short-term dip in annual recurring revenue, while managing ongoing legal disputes and positioning for renewed growth.

HyTerra Ltd has successfully completed drilling and appraisal operations in Kansas, revealing elevated hydrogen and helium concentrations that reinforce the potential of its Nemaha Project. The company is advancing its US market presence with an OTCQB listing and strategic advisory appointments.

Neurizon Therapeutics has secured FDA clearance to resume clinical trials for its lead ALS drug NUZ-001, alongside a $5.2 million capital raise and a key licensing deal with Elanco Animal Health. These developments position the company for a critical growth phase in neurodegenerative disease therapeutics.

Optiscan Imaging Ltd secured $17.75 million in a fully underwritten equity raise, fueling clinical studies and regulatory preparations for its innovative medical imaging devices. The company also reported progress in international trials and strengthened its cash position to nearly $20 million.

Great Northern Minerals Limited has issued a prospectus for an underwritten offer of up to 10,000 listed options at an exercise price of $0.02 each, aiming to facilitate their quotation and trading on the ASX.